BCAL Diagnostics Limited (ASX:BDX), an ASX-listed company and 18.46% substantial shareholder of Genetic Signatures Limited (ASX:GSS), has lodged an application with the Takeovers Panel challenging the proposed merger between GSS and Microba Life Sciences Limited (ASX:MAP), citing concerns over deal protection arrangements and the adequacy of information provided to GSS shareholders.
Key Points
- BDX holds 18.46% of GSS shares on issue and has applied to the Takeovers Panel in relation to GSS's proposed merger with Microba Life Sciences (ASX:MAP).
- The proposed transaction is structured as a scheme of arrangement under which revised terms would see MAP shareholders own 60% and existing GSS shareholders own 40% of the combined group.
- BDX submits that deal protection terms in the scheme implementation deed, including the absence of a fiduciary-out for GSS and a GSS break fee, preclude a competitive market for control of GSS.
- BDX is seeking interim orders to restrain GSS from executing the scheme implementation deed unless it includes an appropriate fiduciary-out, and to prevent Resolution 4 from being put to shareholders at the AGM.
- A sitting Panel has not been appointed and no decision has been made whether to conduct proceedings.
Background to the Proposed GSS–MAP Transaction
Genetic Signatures Limited announced on 26 August 2026 that it was in discussions with Microba Life Sciences Limited regarding a potential merger, with the structure and commercial aspects still under consideration at that time. On 22 September 2026, GSS announced that principal commercial terms had been agreed, with the transaction to be implemented by way of a scheme of arrangement under which MAP shareholders would own approximately 67% of the combined group and GSS shareholders approximately 33%. On 21 October 2026, GSS announced revised terms under which MAP shareholders would own 60% and GSS shareholders 40%.
AGM Notice Addendum and Resolution 4
GSS released its notice of annual general meeting on 16 October 2026, which did not reference the proposed transaction or include any related resolution. Following the announcement of revised terms, GSS released an addendum to the notice on 23 October 2026. The addendum introduced a new Resolution 4, seeking shareholder approval under ASX Listing Rule 7.1 for the issue of securities to MAP under the proposed transaction. The addendum also provided further details of the proposed transaction, including a summary of the material terms of the proposed scheme implementation deed.
Orders Sought by BDX Before the Takeovers Panel
BDX submits that the proposed transaction constitutes a control transaction for GSS without the protections of Chapter 6 of the Corporations Act 2001, and that circumstances are contrary to sections 602(a), 602(b)(ii) and 602(b)(iii). As final orders, BDX seeks that the scheme implementation deed include a fiduciary-out in favour of GSS, that a separate general meeting of GSS shareholders be convened with additional disclosures, and that an independent expert's report be commissioned to opine on the proposed transaction. The Takeovers Panel stated it makes no comment on the merits of the application.




Please wait processing your request...